EPA:DIM • FR0013154002
Past quarterly earnings results for SARTORIUS STEDIM BIOTECH (DIM.PA), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Actual vs estimated values, surprises, q2q growth and acceleration numbers for recent quarters.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 1.12 | 1.28 | -12.72% | 8.74% | 772.2M | 805.83M | -4.17% | 2.78% |
| Q3 2025 | 0.94 | 0.96 | -2.24% | 23.68% | 705.7M | 734.65M | -3.94% | 7.67% |
| Q2 2025 | 1.18 | 1.07 | 10.22% | 38.82% | 745M | 742.74M | 0.30% | 5.46% |
| Q1 2025 | 1.16 | 0.95 | 22.18% | 34.88% | 744.6M | 719.3M | 3.52% | 11.65% |
| Q4 2024 | 1.03 | 0.96 | 7.63% | 43.06% | 751.3M | 730.06M | 2.91% | 6.30% |
| Q3 2024 | 0.76 | 0.81 | -5.62% | -10.59% | 655.4M | 690.73M | -5.11% | -1.72% |
| Q2 2024 | 0.85 | 1.07 | -20.27% | -28.57% | 706.4M | 696.1M | 1.48% | 4.54% |
| Q1 2024 | 0.86 | 0.95 | -9.42% | -39.86% | 666.9M | 726.14M | -8.16% | -8.15% |
| Q4 2023 | 0.72 | 0.85 | -15.13% | -65.05% | 706.8M | 659.45M | 7.18% | -20.58% |
| Q3 2023 | 0.85 | 2.81 | -69.78% | -61.01% | 666.9M | 723.67M | -7.84% | -24.08% |
| Q2 2023 | 1.19 | 2.15 | -44.76% | -45.66% | 675.7M | 709.53M | -4.77% | -21.59% |
| Q1 2023 | 1.43 | 1.44 | -0.76% | -35.29% | 726.1M | 733.36M | -0.99% | -15.81% |
| Q4 2022 | 2.06 | 2.17 | -5.05% | 6.19% | 890M | 917.58M | -3.01% | 14.37% |
| Q3 2022 | 2.18 | 3.05 | -28.54% | 7.39% | 878.4M | 906.82M | -3.13% | -58.35% |
| Q2 2022 | 2.19 | 3.27 | -33.08% | 18.38% | 861.8M | 883.44M | -2.45% | 23.70% |
| Q1 2022 | 2.21 | 2.79 | -20.84% | 34.76% | 862.5M | 787.82M | 9.48% | 31.64% |
| Q4 2021 | 1.94 | 1.83 | 5.83% | 70.18% | 778.177M | 755.82M | 2.96% | 46.64% |
| Q3 2021 | 2.03 | 1.85 | 9.83% | 69.17% | 2.109B | 703.67M | 199.69% | 313.17% |
| Q2 2021 | 1.85 | 1.57 | 18.17% | 94.74% | 696.7M | 670.5M | 3.91% | 55.86% |
| Q1 2021 | 1.64 | 1.46 | 11.98% | 88.51% | 655.2M | 584.79M | 12.04% | 55.22% |
| Q4 2020 | 1.14 | 1.09 | 4.70% | - | 530.681M | 490.04M | 8.29% | - |
| Q3 2020 | 1.20 | 0.95 | 25.73% | - | 510.4M | 456.85M | 11.72% | - |
| Q2 2020 | 0.95 | 0.91 | 4.28% | - | 447M | 454.6M | -1.67% | - |
| Q1 2020 | 0.87 | 0.77 | 13.71% | - | 422.1M | 403.42M | 4.63% | - |
Notes
SARTORIUS STEDIM BIOTECH (DIM.PA) last reported earnings on 2/3/2026.
SARTORIUS STEDIM BIOTECH (DIM.PA) missed EPS estimates and missed revenue estimates in the most recent quarter.
In the last 4 quarters, SARTORIUS STEDIM BIOTECH (DIM.PA) has beaten EPS estimates in 3 out of 4 releases.